(Q41870918)

13 October 2017

Brief report: a double-blind study of naltrexone in infantile autism (English)

1 reference

13 October 2017

0 references

0 references

1

M Leboyer

1 reference

13 October 2017

9

J Panksepp

1 reference

13 October 2017

M P Bouvard

2

1 reference

13 October 2017

J M Launay

3

1 reference

13 October 2017

F Tabuteau

4

1 reference

13 October 2017

D Waller

5

1 reference

13 October 2017

M Dugas

6

1 reference

13 October 2017

B Kerdelhue

7

1 reference

13 October 2017

P Lensing

8

1 reference

13 October 2017

language of work or name

English

0 references

publication date

1 June 1992

1 reference

Journal of Autism and Developmental Disorders

13 October 2017

1 reference

13 October 2017

22

1 reference

13 October 2017

2

1 reference

13 October 2017

309-319

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01058158

13 October 2017

0 references

cites work

Naltrexone in autistic children: an acute open dose range tolerance trial

1 reference

12 December 2020

Endorphin activity in childhood psychosis. Spinal fluid levels in 24 cases.

1 reference

12 December 2020

Low plasma immunoreactive beta-endorphin levels in autism

1 reference

12 December 2020

Homologous regulation of human platelet vasopressin receptors does not occur in vivo

1 reference

12 December 2020

Rationale for the administration of opiate antagonists in treating infantile autism.

1 reference

12 December 2020

Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms.

1 reference

12 December 2020

Naltrexone in infantile autism.

1 reference

12 December 2020

Humoral-endorphin blood levels in autistic, schizophrenic and healthy subjects.

1 reference

12 December 2020

The efficacy and safety of fenfluramine in autistic children: preliminary analysis of a double-blind study.

1 reference

12 December 2020

Naltrexone in autistic children: a double-blind and placebo-controlled study

1 reference

12 December 2020

Brief report: A synopsis of an open-trial of naltrexone treatment of autism with four children

1 reference

12 December 2020

A novel biochemical model linking dysfunctions in brain melatonin, proopiomelanocortin peptides, and serotonin in autism

1 reference

12 December 2020

A case report of naltrexone treatment of self-injury and social withdrawal in autism

1 reference

12 December 2020

Infantile autism: a dysfunction of the opioids?

1 reference

12 December 2020

Naltrexone decreases self-injurious behavior.

1 reference

12 December 2020

Increased Norepinephrine Levels and Decreased Dopamine-β-Hydroxylase Activity in Primary Autism

1 reference

12 December 2020

Tardive and withdrawal dyskinesia in autistic children: a prospective study.

1 reference

12 December 2020

Clinical neurochemistry of autism and associated disorders

1 reference

12 December 2020

Effects on naltrexone on infantile autism.

1 reference

12 December 2020

The Behavioral Summarized Evaluation: validity and reliability of a scale for the assessment of autistic behaviors

1 reference

12 December 2020

Circadian variations in beta-endorphin concentrations in pituitary and in some brain nuclei of the adult male rat

1 reference

12 December 2020

β-Endorphin concentrations in serum, hypothalamus and central gray of hypophysectomized and mediobasal hypothalamus lesioned rats

1 reference

12 December 2020

Effects of acute administration of naltrexone on cardiovascular function, body temperature, body weight and serum concentrations of liver enzymes in autistic children

1 reference

12 December 2020

Brain opioids and autism: an updated analysis of possible linkages

1 reference

12 December 2020

Behavioral and cognitive measures used in psychopharmacological studies of infantile autism.

1 reference

12 December 2020

Catecholamines metabolism in infantile autism: a controlled study of 22 autistic children.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01058158

1 reference

13 October 2017

1 reference